NF1 mutations have been associated with high tumour mutational load and affected patients have been reported to benefit from anti-PD-1 therapy in cutaneous melanoma.42 This suggests that NF1 mutation status has potential as a biomarker for immunotherapy in conjunctival melanoma. The gene discussed is NF1; the disease is malignant conjunctival melanoma.